Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Evaluation of the effectiveness of remdesivir in severe COVID-19 using observational data from a prospective national cohort study

View ORCID ProfileB N Arch, View ORCID ProfileD Kovacs, View ORCID ProfileJ T Scott, View ORCID ProfileA P Jones, View ORCID ProfileE M Harrison, View ORCID ProfileA Rosala-Hallas, View ORCID ProfileC G Gamble, View ORCID ProfileP J M Openshaw, View ORCID ProfileJ K Baillie, View ORCID ProfileM G Semple ISARIC4C Investigators
doi: https://doi.org/10.1101/2021.06.18.21259072
B N Arch
1Liverpool Clinical Trials Centre, Clinical Directorate, Faculty of Health and Life Sciences, University of Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for B N Arch
  • For correspondence: barbara.arch@liverpool.ac.uk
D Kovacs
2Institute of Biodiversity, Animal health and Comparative Medicine, University of Glasgow, Glasgow, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for D Kovacs
J T Scott
3MRC-University of Glasgow Centre for Virus Research, Glasgow, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J T Scott
A P Jones
1Liverpool Clinical Trials Centre, Clinical Directorate, Faculty of Health and Life Sciences, University of Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A P Jones
E M Harrison
4Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for E M Harrison
A Rosala-Hallas
1Liverpool Clinical Trials Centre, Clinical Directorate, Faculty of Health and Life Sciences, University of Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A Rosala-Hallas
C G Gamble
1Liverpool Clinical Trials Centre, Clinical Directorate, Faculty of Health and Life Sciences, University of Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for C G Gamble
P J M Openshaw
5National Heart and Lung Institute, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for P J M Openshaw
J K Baillie
6Roslin Institute, University of Edinburgh, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J K Baillie
M G Semple
7Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK
8Department of Respiratory Medicine, Alder Hey Children’s Hospital, Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M G Semple
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Remdesivir has been evaluated in clinical trial populations, but there is a sparsity of evidence evaluating effectiveness in general populations.

Methods Adults eligible to be treated with remdesivir, requiring oxygen but not ventilated, were identified from UK patients hospitalised with COVID-19. Patients treated with remdesivir within 24h of hospitalisation were compared with propensity-score matched controls; estimates of effectiveness were calculated for short-term outcomes (14-day mortality, 28-day mortality, time-to-recovery among others) using multivariable modelling.

Results 9,278 out of 39,330 patients satisfied eligibility criteria. 1,549 patients were identified as ‘treated’ and matched with 4,964 controls. Patients were 62% male, mean (SD) age 63.1 (15.6) years, 80% ‘White’ ethnicity, and symptomatic for a median of 6 days prior to baseline. There was no statistically significant benefit of remdesivir at 14 days in terms of mortality or clinical status; there were signals of effectiveness in time-to-recovery after day 9, and a reduction in 28-day mortality.

Conclusion In a real-world setting, initiation of remdesivir within 24h of hospitalisation in conjunction with standard of care was not associated with a benefit at 14 days but supports clinical trial evidence of a potential reduction in 28-day mortality.

Competing Interest Statement

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: BNA, ARH, APJ and CGG report: the manufacturer of remdesivir, Gilead, is involved in funding trials that the Liverpool Clinical Trials unit is co-ordinating: a randomised controlled trial (HART-CT) that is fully funded by Gilead and sponsored by the University of Liverpool; and a trial (REALTO) that is part funded by Gilead. APJ is the lead statistician on the HART-CT trial. PJMO reports personal fees from consultancies and from the European Respiratory Society; grants from the Medical Research Council (MRC), MRC Global Challenge Research Fund, EU, NIHR BRC, MRC/GSK, Wellcome Trust, NIHR (Health Protection Research Unit [HPRU] in Respiratory Infection); and is an NIHR senior investigator outside of the submitted work; his role as President of the British Society for Immunology was unpaid but travel and accommodation at some meetings was provided by the Society. MGS reports grants from NIHR UK, MRC UK, and HPRU in Emerging and Zoonotic Infections, University of Liverpool during the conduct of the study.

Clinical Protocols

https://isaric4c.net/protocols

Funding Statement

ISARIC4C is funded by two major awards from the Medical Research Council (MRC; grant MC_PC_19059), and The National Institute For Health Research (NIHR; award CO-CIN-01). PJMO is supported by a NIHR Senior Investigator Award [award 201385]. The Liverpool clinical trials unit did not receive any direct funding for this work. DK is funded by UK MRC Precision Medicine Training Grant (MR/N013166/1-LGH/MS/MED2525). The views expressed are those of the authors and not necessarily those of the NHIR, or MRC.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval for data collection was given by the South Central - Oxford C Research Ethics Committee in England (Ref: 13/SC/0149) and by the Scotland A Research Ethics Committee (Ref: 20/SS/0028).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* Joint 2nd authors

  • One year on from conducting our study, we have updated the paper slightly to reflect it's current relevance as adding to the evidence base rather than presenting novel evidence. It is also updated to incorporate further results published from the WHO SOLIDARITY trial.

Data Availability

This work uses data provided by patients and collected by the NHS as part of their care and support #DataSavesLives. ISARIC4C welcomes applications for data and material access through our Independent Data and Material Access Committee (https://isaric4c.net).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 09, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of the effectiveness of remdesivir in severe COVID-19 using observational data from a prospective national cohort study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evaluation of the effectiveness of remdesivir in severe COVID-19 using observational data from a prospective national cohort study
B N Arch, D Kovacs, J T Scott, A P Jones, E M Harrison, A Rosala-Hallas, C G Gamble, P J M Openshaw, J K Baillie, M G Semple
medRxiv 2021.06.18.21259072; doi: https://doi.org/10.1101/2021.06.18.21259072
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Evaluation of the effectiveness of remdesivir in severe COVID-19 using observational data from a prospective national cohort study
B N Arch, D Kovacs, J T Scott, A P Jones, E M Harrison, A Rosala-Hallas, C G Gamble, P J M Openshaw, J K Baillie, M G Semple
medRxiv 2021.06.18.21259072; doi: https://doi.org/10.1101/2021.06.18.21259072

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (502)
  • Anesthesia (110)
  • Cardiovascular Medicine (1234)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (530)
  • Epidemiology (10015)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2449)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1638)
  • Health Policy (751)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (532)
  • Infectious Diseases (except HIV/AIDS) (11862)
  • Intensive Care and Critical Care Medicine (625)
  • Medical Education (252)
  • Medical Ethics (74)
  • Nephrology (268)
  • Neurology (2278)
  • Nursing (139)
  • Nutrition (350)
  • Obstetrics and Gynecology (453)
  • Occupational and Environmental Health (535)
  • Oncology (1245)
  • Ophthalmology (375)
  • Orthopedics (133)
  • Otolaryngology (226)
  • Pain Medicine (155)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (729)
  • Pharmacology and Therapeutics (311)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4829)
  • Radiology and Imaging (834)
  • Rehabilitation Medicine and Physical Therapy (490)
  • Respiratory Medicine (651)
  • Rheumatology (283)
  • Sexual and Reproductive Health (237)
  • Sports Medicine (226)
  • Surgery (266)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)